Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BRCA1. However, few studies have assessed the association between breast cancer family history and risk of triple-negative breast cancer. We examined the relationship between having a family history of breast cancer in first-degree relatives and risk of triple-negative breast cancer, and risk of two other breast cancer subtypes defined by tumor marker expression. We evaluated data collected by the Breast Cancer Surveillance Consortium from 2,599,946 mammograms on 1,054,466 women, among whom 15% reported a first-degree family history of breast cancer. Using Cox regression in this cohort, we evaluated subtype-specific associations between family history and risk of triple-negative (N = 705), estrogen receptor-positive (ER+, N = 10,026), and hormone receptor-negative/HER2-expressing (ER-/PR-/HER2+, N = 308) breast cancer among women aged 40-84 years. First-degree family history was similarly and significantly associated with an increased risk of all the subtypes [hazard ratio (HR) = 1.73, 95% confidence interval (CI): 1.43-2.09, HR = 1.62, 95% CI: 1.54-1.70, and HR = 1.56, 95% CI: 1.15-2.13, for triple-negative, ER+, and ER-/PR-/HER2+, respectively]. Risk of all the subtypes was most pronounced among women with at least two affected first-degree relatives (versus women with no affected first-degree relatives, HR(triple-negative) = 2.66, 95% CI: 1.66-4.27, HR(ER+) = 2.05, 95% CI: 1.79-2.36, HR(ER)-(/PR)-(/HER2+) = 2.25, 95% CI: 0.99-5.08). Having a first-degree family history of breast cancer was associated with an increased risk of triple-negative breast cancer with a magnitude of association similar to that for the predominant ER+ subtype and ER-/PR-/HER2+ breast cancer.
Phipps
Amanda I
AI
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M4-B402, PO Box 19024, Seattle, WA 98109-1024, USA. aphipps@fhcrc.org
Buist
Diana S M
DS
Malone
Kathleen E
KE
Barlow
William E
WE
Porter
Peggy L
PL
Kerlikowske
Karla
K
Li
Christopher I
CI
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics*; D015331:Cohort Studies; D005192:Family Health; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008327:Mammography / Q000379:methods; D008875:Middle Aged; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics; D012306:Risk
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
AJR Am J Roentgenol. 1997 Oct;169(4):1001-8
9308451
Hum Pathol. 2006 Sep;37(9):1217-26
16938528
Int J Cancer. 1997 May 29;71(5):800-9
9180149
Cancer. 2007 May 1;109(9):1721-8
17387718
Nature. 2000 Aug 17;406(6797):747-52
10963602
Breast Cancer Res Treat. 2009 Jan;113(2):357-70
18324472
Int J Cancer. 2003 Aug 10;106(1):96-102
12794763
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43
17372238
Lancet. 2001 Oct 27;358(9291):1389-99
11705483
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1053-60
14578142
Rev Endocr Metab Disord. 2007 Sep;8(3):255-67
17508290
Am J Hum Genet. 1995 Dec;57(6):1457-62
8533776
Clin Med Res. 2009 Jun;7(1-2):4-13
19574486
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):946-54
16702375
Breast Cancer Res Treat. 2008 May;109(1):123-39
17578664
Int J Cancer. 1997 Sep 4;72(5):735-8
9311586
Am J Epidemiol. 2000 Dec 15;152(12):1154-63
11130621
Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):319-26
7655325
Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52
18768247
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68
15466970
J Clin Oncol. 2006 Dec 20;24(36):5652-7
17116942
Breast Cancer Res Treat. 2009 Apr;114(3):549-58
18437558
J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
14519755
JAMA. 2006 Jun 7;295(21):2492-502
16757721
Breast J. 2009 Nov-Dec;15(6):593-602
19764994